Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 50.70
-0.90 (-1.74%)
Sep 9, 2025, 1:30 PM CST
Tanvex BioPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 110.99 | 34.68 | 61.41 | 22.4 | 5.41 | 0.3 | Upgrade | |
Revenue Growth (YoY) | 221.19% | -43.53% | 174.11% | 314.43% | 1702.00% | - | Upgrade |
Cost of Revenue | 137.62 | 26.39 | 1.71 | 41.75 | 1.86 | 0.16 | Upgrade |
Gross Profit | -26.62 | 8.29 | 59.7 | -19.35 | 3.55 | 0.14 | Upgrade |
Selling, General & Admin | 383.47 | 306.52 | 453.71 | 234.74 | 219.21 | 239.12 | Upgrade |
Research & Development | 896.01 | 1,059 | 1,707 | 1,351 | 1,384 | 1,861 | Upgrade |
Operating Expenses | 1,273 | 1,365 | 2,160 | 1,586 | 1,603 | 2,100 | Upgrade |
Operating Income | -1,300 | -1,357 | -2,101 | -1,606 | -1,599 | -2,100 | Upgrade |
Interest Expense | -49.39 | -53.34 | -57.38 | -54.72 | -46.22 | -18.57 | Upgrade |
Interest & Investment Income | 36.65 | 30.18 | 29.04 | 9.6 | 3.14 | 18.66 | Upgrade |
Currency Exchange Gain (Loss) | 17.98 | 17.98 | 1.32 | 12.48 | 7.16 | -5.63 | Upgrade |
Other Non Operating Income (Expenses) | -110.86 | -19.17 | 1.88 | 4.25 | 92.85 | 1.18 | Upgrade |
EBT Excluding Unusual Items | -1,406 | -1,381 | -2,126 | -1,634 | -1,542 | -2,104 | Upgrade |
Gain (Loss) on Sale of Assets | 0.08 | 0.08 | -2.87 | -7.21 | -0.94 | -0.27 | Upgrade |
Asset Writedown | - | - | -8.67 | - | - | - | Upgrade |
Other Unusual Items | -0.19 | -0.19 | 0.77 | - | - | - | Upgrade |
Pretax Income | -1,406 | -1,381 | -2,137 | -1,641 | -1,543 | -2,104 | Upgrade |
Income Tax Expense | -3.02 | 0.35 | 0.43 | 0.02 | 0.02 | 0.02 | Upgrade |
Net Income | -1,403 | -1,382 | -2,137 | -1,641 | -1,543 | -2,104 | Upgrade |
Net Income to Common | -1,403 | -1,382 | -2,137 | -1,641 | -1,543 | -2,104 | Upgrade |
Shares Outstanding (Basic) | 197 | 155 | 129 | 118 | 109 | 89 | Upgrade |
Shares Outstanding (Diluted) | 197 | 155 | 129 | 118 | 109 | 89 | Upgrade |
Shares Change (YoY) | 40.86% | 20.44% | 9.60% | 8.31% | 21.32% | 9.25% | Upgrade |
EPS (Basic) | -7.11 | -8.90 | -16.58 | -13.95 | -14.21 | -23.51 | Upgrade |
EPS (Diluted) | -7.11 | -8.90 | -16.58 | -13.95 | -14.21 | -23.51 | Upgrade |
Free Cash Flow | -1,253 | -1,257 | -1,506 | -1,427 | -1,417 | -1,854 | Upgrade |
Free Cash Flow Per Share | -6.35 | -8.09 | -11.69 | -12.14 | -13.05 | -20.71 | Upgrade |
Gross Margin | -23.99% | 23.91% | 97.21% | -86.36% | 65.67% | 47.67% | Upgrade |
Operating Margin | -1171.31% | -3912.40% | -3420.80% | -7166.21% | -29581.65% | -699859.00% | Upgrade |
Profit Margin | -1263.84% | -3983.94% | -3480.00% | -7325.16% | -28546.26% | -701412.00% | Upgrade |
Free Cash Flow Margin | -1128.74% | -3623.36% | -2452.94% | -6370.97% | -26208.75% | -617884.67% | Upgrade |
EBITDA | -1,148 | -1,253 | -1,976 | -1,492 | -1,496 | -1,958 | Upgrade |
D&A For EBITDA | 151.61 | 103.76 | 124.89 | 113.22 | 102.84 | 141.87 | Upgrade |
EBIT | -1,300 | -1,357 | -2,101 | -1,606 | -1,599 | -2,100 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.